Germany’s IQWiG: New Year, Same Sternness On Dossier Structure
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer’s kidney cancer drug Inlyta scrapes through the German added value assessment process but Almirall’s COPD product Eklira gets a “thumbs down,” showing that comparator selection is not the only deciding factor in the process.